Juno Therapeutics Inc (NASDAQ:JUNO)‘s stock had its “neutral” rating reaffirmed by research analysts at BTIG Research in a research note issued to investors on Wednesday.

Several other equities analysts also recently issued reports on JUNO. Maxim Group reduced their price objective on Juno Therapeutics from $80.00 to $50.00 and set a “buy” rating for the company in a research report on Friday, August 5th. FBR & Co set a $61.00 price objective on Juno Therapeutics and gave the stock a “buy” rating in a research report on Friday, August 5th. Vetr downgraded Juno Therapeutics from a “strong-buy” rating to a “buy” rating and set a $38.02 target price for the company. in a research report on Tuesday, August 16th. Standpoint Research assumed coverage on Juno Therapeutics in a research report on Thursday, August 25th. They issued a “buy” rating and a $47.00 target price for the company. Finally, Zacks Investment Research upgraded Juno Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, September 6th. Five research analysts have rated the stock with a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus target price of $43.13.

Analyst Recommendations for Juno Therapeutics (NASDAQ:JUNO)

Juno Therapeutics (NASDAQ:JUNO) traded down 27.1416% during mid-day trading on Wednesday, hitting $21.7701. The stock had a trading volume of 15,182,456 shares. Juno Therapeutics has a 12-month low of $19.41 and a 12-month high of $57.82. The firm’s market cap is $2.23 billion. The stock has a 50-day moving average price of $27.93 and a 200 day moving average price of $33.09.

Juno Therapeutics (NASDAQ:JUNO) last issued its earnings results on Wednesday, November 9th. The biopharmaceutical company reported ($0.57) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.52) by $0.05. The business earned $20.80 million during the quarter, compared to the consensus estimate of $10.98 million. During the same period in the prior year, the firm posted ($0.26) EPS. The firm’s revenue for the quarter was up 1200.0% compared to the same quarter last year. Equities analysts anticipate that Juno Therapeutics will post ($2.54) EPS for the current fiscal year.

In other Juno Therapeutics news, EVP Robert Azelby sold 12,921 shares of the stock in a transaction on Thursday, November 10th. The shares were sold at an average price of $24.14, for a total value of $311,912.94. Following the sale, the executive vice president now directly owns 48,640 shares in the company, valued at $1,174,169.60. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Hans Edgar Bishop sold 84,035 shares of the stock in a transaction on Wednesday, September 21st. The stock was sold at an average price of $30.28, for a total transaction of $2,544,579.80. Following the completion of the sale, the chief executive officer now owns 2,518,537 shares in the company, valued at $76,261,300.36. The disclosure for this sale can be found here.

A number of large investors have recently bought and sold shares of the company. Rockefeller Financial Services Inc. raised its stake in Juno Therapeutics by 1,433.2% in the third quarter. Rockefeller Financial Services Inc. now owns 3,465 shares of the biopharmaceutical company’s stock valued at $104,000 after buying an additional 3,239 shares during the period. Advisor Group Inc. raised its stake in Juno Therapeutics by 51.4% in the third quarter. Advisor Group Inc. now owns 3,815 shares of the biopharmaceutical company’s stock valued at $115,000 after buying an additional 1,296 shares during the period. Societe Generale purchased a new stake in Juno Therapeutics during the second quarter valued at $153,000. SG Americas Securities LLC purchased a new stake in Juno Therapeutics during the second quarter valued at $153,000. Finally, Panagora Asset Management Inc. raised its stake in Juno Therapeutics by 55.0% in the third quarter. Panagora Asset Management Inc. now owns 4,200 shares of the biopharmaceutical company’s stock valued at $126,000 after buying an additional 1,490 shares during the period.

TRADEMARK VIOLATION WARNING: This piece was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece on another domain, it was copied illegally and republished in violation of US & international copyright and trademark legislation. The legal version of this piece can be viewed at https://www.thecerbatgem.com/2016/11/23/juno-therapeutics-inc-juno-earns-neutral-rating-from-btig-research.html.

About Juno Therapeutics

Juno Therapeutics, Inc (Juno) is a biopharmaceutical company focused on re-engaging the body’s immune system to revolutionize the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.

5 Day Chart for NASDAQ:JUNO

Receive News & Stock Ratings for Juno Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juno Therapeutics Inc and related stocks with our FREE daily email newsletter.